Every material Form 8-K Eastman Chemical has filed with the SEC since August 01, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Eastman Chemical reported third-quarter 2026 sales of $2,385 million, up from $2,202 million, and diluted EPS of $2.19 versus $0.60 a year earlier. The company projects full-year 2026 adjusted EPS of $6.00 to $6.20 and operating cash flow of about $850 million, while operating cash flow in the quarter fell to $290 million from $402 million.
Q3 2026 sales of $2,385 million, up 8% from $2,202 million, driven mainly by 7% higher selling prices
Diluted EPS of $2.19 vs. $0.60; adjusted diluted EPS of $1.84 vs. $1.14
Full-year 2026 outlook: adjusted EPS of $6.00 to $6.20 and operating cash flow of approximately $850 million
Operating cash flow was $290 million in Q3 2026 vs. $402 million in Q3 2025; the company announced reinstatement of a $375 million U.S. DOE award
Eastman Chemical's board adopted amended and restated bylaws on October 16, 2026, effective immediately, changing how stockholders can nominate directors and submit proposals. The company also set the notice window for stockholder director nominations and other business proposals for its 2027 annual meeting, which matters to shareholders who plan to propose items or nominees.
Board adopted amended and restated bylaws on October 16, 2026, effective immediately
Advance notice window for 2027 annual meeting nominations and proposals: January 7, 2027 to February 6, 2027
Proxy access nominations for the 2027 meeting must be delivered October 25, 2026 to November 24, 2026
Rule 14a-8 stockholder proposal deadline for the 2027 proxy materials remains November 24, 2026
Eastman reported second-quarter 2026 sales of $2,513 million, up 10% from $2,287 million a year earlier, with GAAP diluted EPS of $1.59 versus $1.20 and adjusted EPS of $1.97 versus $1.60. The company now expects 2026 operating cash flow to approach $900 million, modestly below its prior expectation of approaching 2025 levels, and projects third-quarter adjusted EPS to approach the $1.97 second-quarter level.
Second-quarter sales rose 10% to $2,513 million; Chemical Intermediates sales rose 39% while Fibers fell 11%
Adjusted EBIT rose to $320 million from $275 million; GAAP EBIT was $311 million versus $222 million
Operating cash flow was $224 million versus $233 million; full-year 2026 operating cash flow now expected to approach $900 million
Company expects third-quarter 2026 adjusted EPS to approach $1.97 and reaffirmed $125 million to $150 million of cost savings
Eastman Chemical reported first-quarter 2026 sales of $2,177 million, down 5% from $2,290 million a year earlier, and adjusted earnings per diluted share of $1.09 versus $1.91. The company projected second-quarter 2026 adjusted EPS of $1.70 to $1.90, which is well above the first quarter but is a sequential range rather than a comparison to the prior year.
Sales were $2,177 million versus $2,290 million; Fibers fell 22% and Chemical Intermediates fell 9%.
Adjusted EBIT was $200 million versus $311 million; GAAP EPS was $0.93 versus $1.57.
Second-quarter 2026 adjusted EPS is projected at $1.70 to $1.90, with about $45 million of planned maintenance costs.
Net cash used in operating activities was $137 million versus $167 million a year earlier.
Eastman Chemical issued $600 million of 4.500% senior unsecured notes maturing February 20, 2031, with expected net proceeds of approximately $593.7 million. The company plans to use the proceeds for general corporate purposes, including working capital, capital expenditures, and debt repayment. The filing adds to the company's debt obligations but does not report earnings or guidance.
Notes: $600 million aggregate principal, 4.500%, maturing February 20, 2031
Expected net proceeds of approximately $593.7 million after underwriting discounts and offering expenses
Underwriting Agreement dated February 17, 2026, with Barclays, BofA Securities, Citigroup, J.P. Morgan and Mizuho as representatives
Interest paid semi-annually starting August 20, 2026; redeemable at any time before January 20, 2031 at a make-whole price
Eastman reported fourth-quarter 2025 sales of $1,973 million, down 12% from $2,245 million a year earlier, and adjusted diluted EPS of $0.75 versus $1.87. For full-year 2025, adjusted EPS fell to $5.42 from $7.89, and operating cash flow was $970 million versus $1,287 million. The company raised its cost reduction target for 2026 to $125 million to $150 million and guided first-quarter 2026 adjusted EPS to $1.00 to $1.20, but gave no full-year adjusted EPS range.
Q4 2025 sales revenue $1,973 million, down 12%; GAAP diluted EPS $0.92 versus $2.82 a year earlier
FY2025 adjusted EPS $5.42 versus $7.89 in FY2024; cash from operations $970 million versus $1,287 million
2026 cost reduction actions increased to $125 million to $150 million
Q1 2026 adjusted EPS guided to $1.00 to $1.20, excluding possible impact of winter storms; no full-year adjusted EPS range given
Eastman Chemical reported third-quarter 2025 sales of $2.2 billion, down 11% from $2.46 billion a year earlier, and GAAP diluted EPS of $0.40 versus $1.53. The company attributed the decline mainly to lower sales volume, weak consumer demand, and customers reducing tariff-related inventory. It projects full-year 2025 adjusted EPS of $5.40 to $5.65 and operating cash flow approaching $1 billion, which shareholders will weigh against the sharp year-over-year drop in earnings.
Q3 2025 sales were $2,202 million versus $2,464 million in Q3 2024, down 11%; adjusted EBIT was $210 million versus $366 million.
Q3 2025 adjusted diluted EPS was $1.14 versus $2.26 a year earlier; GAAP diluted EPS was $0.40 versus $1.53.
Operating cash flow was $402 million, compared with $396 million in Q3 2024, helped by $204 million of inventory reduction.
Full-year 2025 adjusted diluted EPS is projected at $5.40 to $5.65, and the company expects to reduce costs by more than $75 million net of inflation in 2025.
Chris M. Killian, Senior Vice President and Chief Technology and Sustainability Officer, plans to retire effective December 31, 2025, citing family and health considerations. Stephen G. Crawford, a former executive, is returning to lead technology projects from November 3, 2025, and will take over Killian's role on January 1, 2026, to support a smooth transition.
Killian retires effective December 31, 2025, citing family and health considerations
Crawford returns as Executive Vice President - Technology Projects effective November 3, 2025
Crawford becomes Executive Vice President - Chief Technology Officer and Chief Sustainability Officer on January 1, 2026
Crawford's compensation includes a $705,000 base salary, an $800,000 sign-on bonus, and a $2,200,000 restricted stock unit grant on or about January 2, 2026
Eastman Chemical reported second-quarter 2025 sales of $2.29 billion, down 3% from a year earlier, and adjusted earnings per diluted share of $1.60 versus $2.15. Lower volumes in Fibers, Chemical Intermediates and Advanced Materials drove the decline, and the company projected third-quarter adjusted EPS of about $1.25 and full-year operating cash flow of about $1 billion, with inventory reduction expected to weigh on earnings in the second half.
Q2 2025 sales $2,287 million vs. $2,363 million in Q2 2024; GAAP diluted EPS $1.20 vs. $1.94
Adjusted EBIT $275 million vs. $353 million; operating cash flow $233 million vs. $367 million
Third-quarter 2025 adjusted EPS projected at about $1.25; full-year operating cash flow expected at about $1 billion
Plans to cut inventory by more than $200 million, with a $75 million to $100 million earnings headwind in the back half of 2025
Eastman Chemical's Board appointed Damon Audia as a director on June 27, 2025, to serve until the 2026 Annual Meeting of Stockholders. He joins the Audit, Finance, and Environmental, Safety and Sustainability committees. For shareholders, this is a board composition change that adds a director with a finance background; the filing reports no financial results or guidance.
Damon Audia appointed director on June 27, 2025, term through the 2026 Annual Meeting of Stockholders
Audia named to Audit, Finance, and Environmental, Safety and Sustainability committees
Audia is Senior Vice President and Chief Financial Officer at AGCO Corporation, which the release describes as an $11.7 billion company
Eastman Chemical decided on May 1, 2025 to eliminate the executive vice president position held by Steve Crawford, effective June 2, 2025, after he finished leading startup of the Kingsport Methanolysis facility. The company agreed to pay him 52 weeks of base salary plus up to four months of company-paid healthcare coverage, and his duties will move to other executives.
Position eliminated effective June 2, 2025, as part of ongoing succession planning
Severance of 52 weeks' base salary for 41 years of service
Up to four months of continued healthcare coverage paid by the company
Operational responsibilities transferred to other Eastman executives
Eastman reported first-quarter 2025 sales of $2.29 billion, down 1% from a year earlier, while adjusted earnings per share rose 19% to $1.91 and GAAP diluted EPS rose to $1.57 from $1.39. Cash used in operations widened to $167 million, and the company moved to quarterly adjusted EPS guidance, forecasting second-quarter adjusted EPS of $1.70 to $1.90 amid tariff uncertainty, while cutting its capital expenditure target to around $550 million.
Adjusted EPS of $1.91 versus $1.61 a year earlier; GAAP diluted EPS of $1.57 versus $1.39
Sales revenue of $2.29 billion versus $2.31 billion, with Fibers down 13 percent
Net cash used in operating activities of $167 million versus $16 million, driven by inventory build ahead of a planned second-quarter shutdown
Second-quarter 2025 adjusted EPS guidance of $1.70 to $1.90; cost reduction target raised to approximately $75 million and capital expenditures reduced to around $550 million
Eastman Chemical entered a severance agreement with Brad A. Lich dated March 10, 2025, setting out benefits if he is terminated without Cause or resigns for good reason after March 1, 2027. The filing describes a $2 million cash severance payment plus up to four months of company-paid healthcare, and it does not say whether Lich holds a new or changed role.
Agreement with Brad A. Lich dated March 10, 2025
Qualifying triggers: termination without Cause, or good-reason resignation after March 1, 2027
Cash severance of $2 million plus amounts under existing company plans, and up to four months of paid healthcare coverage
Full agreement to be filed with the Form 10-Q for first quarter 2025
Eastman Chemical issued $250 million of 5.000% notes due August 1, 2029, in a public offering, adding to $500 million of the same notes issued in August 2024. The company expects net proceeds of about $246.2 million for general corporate purposes, including working capital, capital expenditures and debt repayment.
Notes: $250 million principal, 5.000% coupon, maturing August 1, 2029, issued February 21, 2025
Expected net proceeds of approximately $246.2 million after underwriting discounts and offering expenses
Underwriting Agreement dated February 18, 2025, with BofA Securities and J.P. Morgan Securities as representatives
Notes form a single series with the $500 million of 5.000% notes issued August 1, 2024
Eastman Chemical reported fourth-quarter and full-year 2024 results, with sales and per-share earnings both higher than a year earlier. The company also projected 2025 EPS of $8.00-$8.75 and cash from operations of about $1.3 billion.
Q4 2024 sales were $2,245 million, up 2% from $2,207 million; GAAP diluted EPS was $2.82 versus $2.61, and adjusted EPS was $1.87 versus $1.31.
Full-year 2024 sales were $9,382 million, up from $9,210 million; GAAP diluted EPS was $7.67 versus $7.49, and adjusted EPS was $7.89 versus $6.40.
Q4 2024 GAAP earnings before interest and taxes fell to $349 million from $477 million, which included a 2023 gain on the Texas City sale.
For 2025, the company expects EPS of $8.00-$8.75 and cash from operations of about $1.3 billion.
Eastman reported third quarter 2024 sales of $2.46 billion, up 9% from $2.27 billion a year earlier, with GAAP diluted EPS of $1.53 versus $1.49 and adjusted diluted EPS of $2.26 versus $1.47. The company kept the midpoint of its full-year adjusted EPS guidance unchanged and expects 2024 EPS of $7.50 to $7.70, while saying the Kingsport methanolysis facility has taken longer than expected to reach consistent production rates.
Third quarter sales were $2,464 million versus $2,267 million, driven by an 8% increase in sales volume/mix.
GAAP diluted EPS was $1.53 versus $1.49; adjusted diluted EPS was $2.26 versus $1.47.
The company expects 2024 EPS of $7.50 to $7.70 and cash from operations of approximately $1.3 billion, with the adjusted EPS guidance midpoint unchanged.
Eastman made an investment decision to build a second methanolysis facility in Longview, Texas, and returned $195 million to shareholders in the quarter, including $100 million of share repurchases.
Eastman Chemical Company issued $500 million of 5.000% notes maturing August 1, 2029, in a public offering that closed on August 1, 2024. The company expects net proceeds of about $494.4 million and plans to use part of them for a concurrent tender offer for up to $250 million of its 3.800% notes due 2025, with any remainder for general corporate purposes.
$500 million aggregate principal of 5.000% notes due August 1, 2029, issued August 1, 2024
Expected net proceeds of approximately $494.4 million after underwriting discounts and estimated expenses
Concurrent tender offer for up to $250 million of 3.800% notes due 2025; interest on new notes paid February 1 and August 1, starting February 1, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Eastman Chemical filing is on SEC EDGAR ↗. 8-K briefs of other companies →